Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
The ruling Liberal Democratic Party (LDP) and its junior coalition partner Komeito have submitted their respective proposals to the government, calling for careful discussions on so-called “off-year” drug re-pricing in view of the impact of the novel coronavirus pandemic. In…
To read the full story
Related Article
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
July 16, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…